Glioblastoma (GBM), the most common and extremely lethal type of brain tumor, is resistant to treatment and shows high recurrence rates. In the last decades, it is indicated that standard two-dimensional (2D) cell culture is inadequate to improve new therapeutic strategies and drug development. Hence, well-mimicked three-dimensional (3D) tumor platforms are needed to bridge the gap between in vitro and in vivo cancer models. In this study, bacterial cellulose nano-crystal (BCNC) containing polycaprolactone (PCL) /gelatin (Gel) nanofibrous composite scaffolds were successfully fabricated by electrospinning for mimicking the extracellular matrix of GBM tumor. The fiber diameters in the nanofibrous matrix were increased with an increased concentration of BCNC. Moreover, fiber morphology changed from the smooth formation to the beaded formation by increasing the concentration of the BCNC suspension. In-vitro biocompatibilities of nanofibrous scaffolds were tested with U251 MG glioblastoma cells and improved cell adhesion and proliferation was compared with PCL/Gel. PCL/Gel/BCNC were found suitable for enhancing axon growth and elongation supporting communication between tumor cells and the microenvironment, triggering the process of tumor recurrence. Based on these results, PCL/Gel/BCNC composite scaffolds are a good candidate for biomimetic GBM tumor platform.

中文翻译：

---

胶质母细胞瘤细胞通过聚己内酯/明胶电纺纳米纤维中细菌纤维素纳米晶体的粘附特性。

胶质母细胞瘤（GBM）是最常见且致死性极强的脑肿瘤，对治疗有抵抗力，并且复发率很高。在过去的几十年中，这表明标准的二维（2D）细胞培养不足以改善新的治疗策略和药物开发。因此，需要良好模仿的三维（3D）肿瘤平台来弥合体外和体内癌症模型之间的差距。在这项研究中，成功​​地通过电纺丝模拟了GBM肿瘤的细胞外基质，成功地制备了包含聚己内酯（PCL）/明胶（Gel）纳米纤维复合支架的细菌纤维素纳米晶体（BCNC）。纳米纤维基质中的纤维直径随着BCNC浓度的增加而增加。而且，通过增加BCNC悬浮液的浓度，纤维形态从光滑形态变为珠状形态。用U251 MG胶质母细胞瘤细胞测试了纳米纤维支架的体外生物相容性，并与PCL / Gel比较了改善的细胞黏附和增殖。发现PCL / Gel / BCNC适合增强轴突生长和延长，支持肿瘤细胞与微环境之间的通讯，从而触发肿瘤的复发过程。基于这些结果，PCL / Gel / BCNC复合支架是仿生GBM肿瘤平台的良好候选者。发现PCL / Gel / BCNC适合增强轴突生长和延长，支持肿瘤细胞与微环境之间的通讯，从而触发肿瘤的复发过程。基于这些结果，PCL / Gel / BCNC复合支架是仿生GBM肿瘤平台的良好候选者。发现PCL / Gel / BCNC适合增强轴突生长和延长，支持肿瘤细胞与微环境之间的通讯，从而触发肿瘤的复发过程。基于这些结果，PCL / Gel / BCNC复合支架是仿生GBM肿瘤平台的良好候选者。